作者: KA Foon , J Zighelboim , C Yale , RP Gale
DOI: 10.1182/BLOOD.V58.3.467.BLOODJOURNAL583467
关键词:
摘要: One-hundred and seven patients with acute myelogenous leukemia (AML) ranging in age from 15 to 82 yr who were previously untreated, received a 70 day high-dose remission induction regimen consisting of daunorubicin, cytarabine, thioguanine (TAD). Identical complete rates 65% observed for 33 60 older 74 15–59 yr. Median duration survival 14 mo 22 older, 16 These differences are not significant. data indicate that respond intensive chemotherapy similar manner younger this disease.